Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huya Japan
San Diego, California, United States
- Ownership
- Private
- Employees
- ~118
- Development stage
- Other
01
Overview
HBI-8000 is approved in China for PTCL under the brand name Epidaza, approved in Japan for PTCL under the brand name Hiyasta, and in clinical trials in the U.S. for solid tumors in combination with nivolumab[1][2][4][6]. HBI-3000 is in Phase 2 development for cardiac arrhythmia[4].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small moleculeHistone deacetylase inhibitor
- Industry
- Biotech
02
Partnerships
Eisai Co. Ltd (HBI-8000 rights in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Singapore)Fudan University (IDO inhibitor platform license)Korea Drug Development Fund (KDDF)
Beyond the preview
Go deeper on Huya Japan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huya Japan.